Taiho Pharmaceutical and Arcus Biosciences (RCUS) announced that Taiho exercised its option to develop and, if approved, commercialize casdatifan, an investigational small molecule HIF-2alpha inhibitor, in Japan and certain other territories in Asia. This option exercise is based on a 2017 option and license agreement between Taiho and Arcus. This is the fifth option exercise by Taiho to an Arcus program. In exchange for the exclusive license to casdatifan, Taiho will make an option exercise payment, as well as additional payments upon achievement of clinical, regulatory and commercialization milestones, and, if any products from the program are approved, will pay royalties on net sales of such products.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCUS:
- Arcus Biosciences Reports Promising Phase 2 Study Results
- Arcus Biosciences price target raised to $54 from $47 at Citi
- Positive Outlook for Arcus Biosciences Driven by Promising Phase 2 Trial Results and Broader Patient Applicability
- Arcus announces first OS results from Arm A1 of Phase 2 EDGE-Gastric study
- Arcus Biosciences price target raised to $39 from $32 at Truist